Dermata Therapeutics Inc (DRMA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access DRMA Annual Balance Sheets →
Quarterly balance sheet trends provide context on Dermata Therapeutics Inc's liquidity, leverage, and long-term financial structure.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent4.41
Cash & Short-term Investments4.00
Inventories0.15
Prepaid Expense And Other Assets Current0.67
Total Current Assets5.16
Equipment/Property/Plant Net0.13
Other Assets, Noncurrent0.04
Total Assets5.32
Liabilities
Accounts Payable, Current AC1.12
Accrued Liabilities And Other Liabilities0.34
Total Current Liabilities1.46
Total Long-term Debt0.00
Other liabilities, Noncurrent0.37
Total Liabilities1.83
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock81.54
Retained Earnings / Accumulated Deficit-78.05
Other Equity0.00
Common Stockholder's Equity3.49
Total Stockholder's Equity3.49
Liabilities & Stockholder's Equity5.32
4 historic quarters locked

Sign in to unlock the full Dermata Therapeutics Inc balance sheet history.

About Dermata Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 11, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-037127

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.